A Phase II Single Arm Clinical Trial to Evaluate the Efficacy and Safety of the Combination of Tarceva™ (Erlotinib Hydrochloride) and Rapamune™ (Sirolimus) in the Treatment of Metastatic Renal Cell Carcinoma.
Overview
- Phase
- Phase 2
- Intervention
- Erlotinib hydrochloride
- Conditions
- Renal Cell Carcinoma
- Sponsor
- University of Colorado, Denver
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- Progression-free Survival
- Status
- Completed
- Last Updated
- 12 years ago
Overview
Brief Summary
The purpose of this study is to test the safety and efficacy of the combination of erlotinib hydrochloride (Tarceva™) and sirolimus (Rapamune™) in the treatment of patients with metastatic kidney cancer.
Detailed Description
Despite recent advances metastatic renal cell carcinoma remains an incurable condition. Currently available treatment with high-dose interleukin-2 can lead to complete responses in a small minority of selected patients but is markedly toxic and not broadly available. FDA-approved multikinase inhibitors (sorafenib and sunitinib malate) often cause partial and transient tumor regression. There is no standard treatment metastatic renal cell carcinoma for patients whose disease progressed on multikinase inhibitors. The kinase mammalian target of rapamycin (mTOR) is overstimulated in a subset of renal cell carcinomas and other malignancies and can be blocked by sirolimus leading to growth arrest. Erlotinib hydrochloride is a drug that blocks the function of the epidermal growth factor receptor (EGFR), often over expressed in kidney cancer. Sirolimus and EGFR inhibitors and been safely used in combination. In vitro experiments show that erlotinib enhances the sirolimus induced growth impairment in a panel of renal cell carcinoma cells. In the present study patients with metastatic renal cell carcinoma whose disease progressed on multikinase inhibitors will be treated with the combination of erlotinib hydrochloride (Tarceva™) and sirolimus (Rapamune™). This is a single arm trial with no placebo or drug-based control arm
Investigators
Eligibility Criteria
Inclusion Criteria
- •Signed informed consent to participate in this study.
- •Histological diagnosis of renal cell carcinoma.
- •Age greater or equal 18 years.
- •Eastern Cooperative Oncology Group (ECOG) Performance status of 2 or better.
- •Life expectancy of at least 3 months.
- •Failure or intolerance to previous treatment with Sutent® and/or Nexavar®.
- •Most recent systemic treatment at least 1 month from the beginning of treatment.
- •Most recent local treatment (surgery or irradiation) \> 2 weeks from the beginning of treatment.
- •At least one site of measurable disease by CT scan or MRI (RECIST criteria).
- •Baseline hemoglobin \>9 g/dl, platelets \> 100,000/mm3, absolute neutrophil count (ANC \>1500/mm3.
Exclusion Criteria
- •Previous treatment with Tarceva™, Iressa™, Rapamune™, temsirolimus or everolimus.
- •Untreated metastasis to the central nervous system.
- •Previous solid organ, bone marrow or stem-cell transplant.
- •Known AIDS or HIV infection.
- •Symptomatic or poorly controlled chronic heart failure.
- •Chronic renal failure requiring dialysis on a regular basis.
- •Chronic liver failure.
- •Serum aspartate aminotransferase (AST), Alanine Aminotransferase (ALT), alkaline phosphatase or bilirubin \>1.5 x the upper limit of normal for the local laboratory.
- •Pregnant or breast-feeding women.
- •Other invasive malignant diseases within 5 years (other than squamous or basal cell carcinoma of the skin).
Arms & Interventions
Erlotinib and Sirolimus
Erlotinib hydrochloride (Tarceva) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single-agent Tarceva, 150 mg/day. Sirolimus (Rapamune) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
Intervention: Erlotinib hydrochloride
Erlotinib and Sirolimus
Erlotinib hydrochloride (Tarceva) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single-agent Tarceva, 150 mg/day. Sirolimus (Rapamune) will be self-administered in an open-label unblinded manner to all patients enrolled in the study. Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
Intervention: Sirolimus
Outcomes
Primary Outcomes
Progression-free Survival
Time Frame: Physical exam assessments were performed every 4 weeks during the treatment phase. Survival follow-up information was collected every 4 months following the termination visit until death, loss to follow-up, or study termination up to 275 weeks.
Time to progression was defined as the time from beginning of therapy until disease progression or death. For subjects who had not progressed at the time of statistical analysis, progression-free survival was censored at the date of their last tumor assessment. Kaplan-Meier method was used to estimate median progression-free survival. Progression was defined as radiographic progression according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria (year 2000 version), non-compliance in obtaining scans, unequivocal clinical progression or the initiation of another medication for the treatment of renal cell carcinoma.
Secondary Outcomes
- Overall Survival(Survival follow-up information was collected every 4 months following the termination visit until death, loss to follow-up, or study termination up to 275 weeks.)